A trial looking at zalutumumab with radiotherapy for head and neck cancer (GEN207)

Cancer type:

Head and neck cancers
Laryngeal cancer
Mouth (oral) cancer

Status:

Results

Phase:

Phase 1/2

This trial was looking at zalutumumab with radiotherapy for cancer of the mouth or cancer of the voice box (larynx) that is locally advanced.

Doctors often treat locally advanced cancer of the mouth or cancer of the larynx with chemotherapy and radiotherapy together. They most often use platinum chemotherapy drugs. But some people are not able to have platinum drugs.

Zalutumumab is a type of biological therapy called a monoclonal antibody. We knew from laboratory studies that zalutumumab may stop or slow down the growth of cancer cells.

The aim of this trial was to find the maximum dose of zalutumumab to use with radiotherapy.

Summary of results

This trial was never finished so there are no results available.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Prof Chris Nutting

Supported by

Experimental Cancer Medicine Centre (ECMC)
Genmab
NIHR Clinical Research Network: Cancer

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

Oracle 3749

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Around 1 in 5 people take part in clinical trials

3 phases of trials

Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think

Share this page